RCT for Transvaginal Self-cut Mesh vs Mesh-kit for Severe POP

Sponsor
Peking Union Medical College Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT03849157
Collaborator
Shanghai Medstron Medical Co.Ltd (Other), Chinese Academy of Medical Sciences (Other), LinkDoc Technology (Beijing) Co. Ltd. (Industry)
312
11
2
48
28.4
0.6

Study Details

Study Description

Brief Summary

Pelvic organ prolapse(POP) is a common health problem and has significant negative effects on woman's quality of life. Transvaginal mesh procedure is a durable reconstructive surgery, but the mesh kits are expensive for underdeveloped countries. Our preliminary trial showed that the use of self-tailored mesh had good success rate (91.8% at 1-year follow-up) and low complication rate. The trial is designed to compare self-tailored titanium-coated polypropylene mesh procedure with mesh-kit in the treatment of POP stage III-IV in terms of efficacy, safety and cost-effective .

Condition or Disease Intervention/Treatment Phase
  • Procedure: pelvic floor reconstructive surgery
N/A

Detailed Description

The trial is a randomized controlled multi-center non-inferiority trial. The primary outcome measure is success rate at 1-year follow-up. The second outcomes are subjective improvement of quality of life, complications and costs. Analysis will be performed according to the intention to treat principle. Based on comparable success rate of 90% and 10% as the margin(beta 0.2 and one sided alpha 0.025), about 312 patients in total from 11 centers will be recruited per group including 10% drop-out. The aims of the research are to demonstrate whether self-tailored mesh is non-inferior to the mesh-kit. The finding of this research might influence the treatment selection for POP in China.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
312 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Masking Description:
participant and investigator are not blinded. outcome assessor who are in charge of follow-up assement is masked.
Primary Purpose:
Treatment
Official Title:
A Multicenter Randomized Controlled Non-inferiority Trial Comparing Transvaginal Self-tailored Titanium-coated Polypropylene Mesh Procedure With Mesh-kit Procedure.
Actual Study Start Date :
Jan 12, 2018
Anticipated Primary Completion Date :
Jan 12, 2020
Anticipated Study Completion Date :
Jan 12, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: self-cut mesh procedure

This procedure is transvaginal mesh implantation surgery for POP patients. Self-cut mesh procedure is an economic pelvic reconstructive surgical operation with use of specially designed puncture needles and self-cut mesh, which mainly provide anterior and apical compartments support, with posterior compartment reinforced by bridge technique repair. The mesh pieces used in this surgery was cut from a single piece of mesh material(TiLOOP 10*15cm) which is much cheaper and readily available. Patients could have transvaginal hysterectomy concomitantly.

Procedure: pelvic floor reconstructive surgery
transvaginal mesh implantation for pelvic organ prolapse

Active Comparator: mesh-kit procedure

This procedure is transvaginal mesh implantation surgery for POP patients.Mesh-kit procedure is refered to pelvic floor reconstructive surgery with titanium-coated meshes kit(TiLOOP TOTAL6).Patients could have transvaginal hysterectomy concomitantly.

Procedure: pelvic floor reconstructive surgery
transvaginal mesh implantation for pelvic organ prolapse

Outcome Measures

Primary Outcome Measures

  1. surgical "success" [up to 36 months after operation]

    Subjects will be considered a success if they meet the definitions of anatomic cure and deny vaginal bulging symptoms, and no additional treatment for prolapse(surgical or pessary use). Anatomic cure is defined as leading edge above the hymen (i.e Ba, C, Bp<0 cm) Symptomatic cure is defined as the absence of vaginal bulge symptoms as indicated by a negative response question 3 of the pelvic floor distress inventory- 20 (PFDI-20): "Do you usually have a bulge or something falling out that you can see or feel in your vaginal area?

Secondary Outcome Measures

  1. anatomic outcomes [up to 36 months after operation]

    anatomic outcome of each vaginal segment( anterior, posterior and apical) using POP-Q score.

  2. symptomatic improvement using validated instruments(PFIQ-7) [up to 36 months after operation]

    Relief of symptoms using validated instruments(PFIQ-7) .

  3. symptomatic improvement using validated instruments(PFDI-20) [up to 36 months after operation]

    Relief of symptoms using validated instruments(PFDI-20) .

  4. symptomatic improvement using validated instruments(PISQ-12) [up to 36 months after operation]

    Relief of symptoms using validated instruments(PISQ-12)

  5. symptomatic improvement using patient global impression of change (PGI-C) [up to 36 months after operation]

    Relief of symptoms using patient global impression of change (PGI-C)

  6. intraoperative and post operative complications [up to 36 months after operation]

    using IUGA/ICS joint terminology CTS coding system and dingo system

  7. post operative pain [within 3 days after operation]

    visual analogue scales (VAS) were used to evaluate the degree of pain.

Eligibility Criteria

Criteria

Ages Eligible for Study:
53 Years to 75 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age:More than 50 year with more than 3 years after menopause, or more than 55 years old, but less than 75 years old.

  • Subject must have severe apical or anterior vaginal prolapse (stage III-IV), with moderate posterior vaginal prolapse(stage I-II). This is defined as ( C > +1cm OR Ba > +1cm, with Bp ≤+1cm by the POP-Q). This is the most common modality of multiple compartment POP in clinic.

  • Subject reports a bothersome bulge they can see or feel per PFDI-20, question 3, response of 2 or higher (i.e., responses of "somewhat", "moderately", or "quite a bit").

  • Desires transvaginal mesh treatment for primary or recurrent, symptomatic uterovaginal prolapse.

  • Concomitant hysterectomy when indicated. But concomitant anti-incontinence surgeries will not be enrolled.

  • Subject is willing and able to comply with the follow-up regimen.

Exclusion Criteria:
  • Subject is pregnant or intends to become pregnant in the future

  • Subject has an active or chronic systemic infection including any gynecologic infection, untreated urinary tract infection (UTI) or tissue necrosis

  • Subject has history of pelvic organ cancer (e.g. uterine, ovarian, bladder, colo-rectal or cervical)

  • Subject has had prior or is currently undergoing radiation, laser therapy, or chemotherapy in the pelvic area

  • Subject has taken systemic steroids (within the last month), or immunosuppressive or immunomodulatory treatment (within the last 3 months)

  • Subject has systemic connective tissue disease (e.g. scleroderma, systemic lupus erythematosus (SLE), Marfan syndrome, Ehlers Danlos, collagenosis, polymyositis, polymyalgia rheumatica)

  • Subject has chronic systemic pain that includes the pelvic area or chronic focal pain that involves the pelvis

  • Subject has uncontrolled diabetes mellitus (DM)

  • Subject has a known neurologic or medical condition affecting bladder function (e.g., multiple sclerosis, spinal cord injury or stroke with residual neurologic deficit)

  • Subject has had previous prolapse repair with mesh in the target compartment

Contacts and Locations

Locations

Site City State Country Postal Code
1 Peking Union Medical College Hospital Beijing Beijing China
2 Fosha Maternal and Child Health Care Hospital Foshan Guangdong China
3 The First Affiliated Hospital of Guangzhou Medical College Guangzhou Guangdong China
4 Changsha Maternal and Child Health Care Hospital Changsha Hunan China
5 The second Xiangya Hospital of Central South University Changsha Hunan China
6 Wuxi Maternal and Child Health Care Hospital Wuxi Jiangsu China
7 Qilu Hospital of Shandong University Jinan Shandong China
8 Shanxi Provincial People's Hospital Xi'an Shanxi China
9 Sichuan University West China Second University Hospital Chengdu Sichuan China
10 the First Affiliated Hospital of Xinjiang Medical University Ürümqi Xinjiang China
11 the People's Hospital of Xinjiang Uygur Autonomous Region Ürümqi Xinjiang China

Sponsors and Collaborators

  • Peking Union Medical College Hospital
  • Shanghai Medstron Medical Co.Ltd
  • Chinese Academy of Medical Sciences
  • LinkDoc Technology (Beijing) Co. Ltd.

Investigators

  • Principal Investigator: Lan Zhu, Peking Union Medical College Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Peking Union Medical College Hospital
ClinicalTrials.gov Identifier:
NCT03849157
Other Study ID Numbers:
  • protocol for TVM
First Posted:
Feb 21, 2019
Last Update Posted:
Feb 21, 2019
Last Verified:
Feb 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 21, 2019